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We report 74 patients in Italy infected with Mansonella 
perstans nematodes, a poorly described filarial parasite. 
M. perstans nematodes should be included in the differen-
tial diagnosis for patients with eosinophilia from disease- 
endemic countries. Serologic analysis is useful for screen-
ing, and testing for microfilaremia in peripheral blood should 
be performed for parasite-positive patients.
Mansonella perstans is a filarial nematode present in 33 countries in sub-Saharan Africa; sporadic cases have 
been reported in Latin America, mostly in the Caribbean and 
along the Atlantic coast (1); ≈20% of inhabitants of disease-
endemic countries are infected (2). Flies of the genus Culi-
coides transmit infective larvae to humans. Larvae transform 
into macrofilariae, which live in serous cavities of the human 
body, where they produce microfilariae, which are released 
into peripheral blood 9–12 months after infection.
Few studies/case series have reported signs and symp-
toms (e.g., subcutaneous edema, rash, abdominal pain, 
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eosinophilia) caused by infection with M. perstans nema-
todes because the parasite is widespread in remote areas 
and infected persons usually have other parasitic infec-
tions that could contribute to clinical manifestations (1). 
Diagnosis is based on detection of microfilariae in periph-
eral blood (3). An ELISA that uses antigens of Acantho-
cheilonema vitae nematodes is available but is not specific 
for Mansonella spp.
Optimal treatment is still debated. Many drugs have 
been used, including diethylcarbamazine, ivermectin, 
mebendazole, levamisole, albendazole, and thiabendazole 
(1). Doxycycline, which is active against the endosymbi-
ont Wolbachia spp., showed good efficacy in a clinical trial 
(4), but comparisons of the efficacy of this drug with other 
treatments are lacking. Most case series identified in coun-
tries to which M. perstans nematodes are not endemic have 
not been reported. The purpose of this study was to analyze 
the clinical, epidemiologic, and laboratory characteristics 
of patients infected with M. perstans nematodes who were 
given a diagnosis at the Center for Tropical Diseases at Sa-
cro Cuore Hospital in Negrar, Verona, Italy.
The Study
This retrospective study was approved by the Ethics Com-
mittee of Sacro Cuore Hospital in November 2016 (study 
protocol no. 56014). We reviewed medical records of pa-
tients admitted to Sacro Cuore Hospital during January 1, 
1993–January 1, 2016. Inclusion criteria were available 
information about the most likely country of acquisition 
of the infection and presence of M. perstans microfilare-
mia (Figure 1).
A total of 82 patients were considered for inclusion; 8 
were excluded because information was incomplete. Thus, 
74 patients, 23 immigrants and 51 expatriates, were included 
in the analysis. Immigrants were persons who were born in 
disease-endemic areas and then settled in Italy. Expatriates 
were persons from Italy residing in disease-endemic areas. 
Immigrants were younger than expatriates. Mean ages were 
26.8 (range 5–51) years for immigrants and 55.6 (range 12–
76) years for expatriates. Most (70.3%) patients were males.
We detected microfilaremia by using a leukocon-
centration method with 13-mL samples of venous blood. 
Figure 1. Microfilaria in a patient infected with Mansonella 
perstans nematodes, Italy. Giemsa stain, 200 µm x 4 µm, original 
magnification x1,000.
Figure 2. Countries of 
origin of patients infected 
with Mansonella perstans 
nematodes, Italy. A) Immigrants; 
B) expatriates. Immigrants 
were persons who were born 
in disease-endemic areas and 
then settled in Italy. Expatriates 
were persons from Italy residing 
in disease-endemic areas.
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 9, September 2017 1541
Microfilarial density was measured by examination of 
Giemsa-stained thick blood smears prepared from 100 µL 
of blood. We also performed retrospective ELISA for de-
tection of filariasis (Bordier Affinity Products SA, Crissier, 
Switzerland) on available serum samples.
When necessary, we conducted other investigations 
to exclude other parasitic infections or other causes of eo-
sinophilia. Other helminth infections were diagnosed by 
microscopic examination of multiple stool samples; agar 
stool culture (for hookworm and Strongyloides stercora-
lis); skin-snip (for Onchocerca volvulus); and serologic 
analysis (in-house immunofluorescence test for S. sterco-
ralis; commercial immunofluorescence test until 2012, and 
an ELISA after 2012 for Schistosoma spp).
For each patient, information on clinical history, 
country of exposure, laboratory examinations, and treat-
ment was obtained from medical records and entered 
into a study-specific database (Epi Info version 3.5.1; 
Centers for Disease Control and Prevention, Atlanta, 
GA, USA). Qualitative data were reported as frequen-
cies and percentages, and quantitative data as medians 
and interquartile ranges.
We identified countries in which M. perstans infec-
tions were acquired (Figure 2), and clinical and labora-
tory characteristics of the 74 patients (Table 1) and char-
acteristics of patients who were infected only with M. 
perstans nematodes (33/74, 44.6%) (Table 2). However, 
we could not exclude other possible co-infections on the 
basis of screening tests performed (e.g., 23/33 patients 
came from country to which Loa loa, another filarial 
nematode, was endemic, and amicrofilaremic infections 
cannot be ruled out).
Data for treatment were available for 60 (81.1%) of 74 
patients. Most (34/60, 56.6%) patients were treated with 
levamisole (150 mg in 3 doses given every 48 h), followed 
by mebendazole (500 mg 3×/d for 15 d). After 2004, le-
vamisole was no longer available, and patients were then 
treated with other drugs alone or in combination (doxycy-
cline, mebendazole, ivermectin, diethylcarbamazine, al-
bendazole, thiabendazole). Since 2009, first-line treatment 
has been mebendazole (500 mg 3×/d for 15 d), followed 
by doxycycline (100 mg 2×/d for 6 wks); this regimen was 
used for 11 (18.3%) of 60 patients. Clinical outcomes were 
available for only 5 of those patients, who showed com-
plete clinical responses to the first-line treatment.
Conclusions
Our series of 74 patients is one focused on imported in-
fections with M. perstans nematodes. Identification these 
infections is often complicated by co-infection with other 
infective agents. Bassene et al. analyzed patients infected 
only with M. perstans nematodes and concluded that these 
infections had little pathogenicity because infected persons 
were usually asymptomatic (5). Therefore, we considered 
as relevant identification of patients for whom other infec-
tions were excluded.
Our findings for this subgroup of patients are similar 
to those reported by Adolph et al. (6); however, we did 
not observe any major neurologic or psychological symp-
toms or extreme exhaustion. Among symptoms that we 
observed, transient swellings deserve particular attention. 
These swellings are similar to Calabar swellings caused 
by L. loa nematodes. When L. loa nematode infections are 
ruled out on the basis of an epidemiologic criterion (loiasis 
 
Table 1. Characteristics of 74 patients infected with Mansonella 
perstans nematodes, Italy* 
Characteristic Value 
Age, y  48.9 (34.060.6) 
Sex  
 M 52 (70.3) 
 F 22 (29.7) 
Viral co-infections  
 HIV 4 (5.4) 
 HBV 3 (4.0) 
 HCV 3 (4.0) 
 HAV 1 (1.3) 
Parasite diseases  
 Plasmodium falciparum malaria 9 (12.1) 
 Giardiasis 2 (2.7) 
 Scabies 1 (1.3) 
Other helminthiases  
 Schistosomiasis 27 (36.4) 
 Strongyloidiasis 11 (14.9) 
 Hookworm infection 7 (9.4) 
 Loiasis 4 (5.4) 
 Trichuriasis 4 (5.4) 
 Onchocerciasis 2 (2.7) 
Eosinophils/mm3 820 (470–1,270) 
Eosinophil count >1,000/µL 32/73 (43.8) 
Microfilaria/mL 62 (14–255) 
Signs/symptoms 66 (89.2) 
 Abdominal pain 17 (23.0) 
 Arthralgia 10 (13.5) 
 Headache 11 (15.0) 
 Itching 25 (33.8) 
 Myalgia 2 (3.0) 
 Edema 11 (14.9) 
 Skin eruption 9 (12.2) 
IgE >100 IU/mL 60/72 (83.3) 
Antifilarial ELISA  49/53 (92.4) 
*Values are median (IQR), no. (%), or no. positive/no. tested (%). HAV, 
hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; IQR, 
interquartile range. 
 
 
Table 2. Characteristics of 33 patients infected only with 
Mansonella perstans nematodes, Italy* 
Characteristic Value 
Eosinophils/mm3 620 (415–1,210) 
Microfilaria/mL 32 (9.5–112) 
Signs/symptoms 30 (90.9) 
 Abdominal pain 8 (24.2) 
 Arthralgia 5 (15.1) 
 Headache 5 (15.1) 
 Itching 12 (36.3) 
 Edema 6 (18.2) 
 Skin eruption 3 (9.1) 
*Values are median (IQR) or no. (%). IQR, interquartile range. 
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is present in a limited area of sub-Saharan Africa), M. per-
stans nematodes should be considered the probable cause 
of these swellings.
The proportion of patients with different grades of 
eosinophilia in our study is similar to that reported by 
Wiseman (7): ≈70% of those patients had >500 eosino-
phils/µL, and 45% had marked eosinophilia (>1,000 eo-
sinophils/µL). Wiseman postulated that the proportion of 
symptomatic patients increased with increased eosinophil 
count (7). Conversely, increased eosinophil counts could 
be partially responsible for some symptoms, as reported 
by Fux et al. (8).
Of the 74 patients in our study, 68 (92.0%) had posi-
tive serologic results. One major strength of our study was 
that serologic analysis could be used to screen patients re-
porting compatible symptoms/signs and epidemiologic cri-
teria. Thus, microscopic detection of microfilaremia, which 
requires more equipment and skills, could be used only for 
patients with positive serologic results.
Human infection with M. perstans nematodes raises 
questions about treatment (1) because of poor responses 
to standard antifilarial drugs and limited findings from 
controlled trials. In our case series, the first-line treat-
ment changed over time on the basis of new evidence 
and availability of drugs. Therefore, we first administered 
mebendazole and levamisole on the basis of reports by 
Maertens and Wéry (9) and Wahlgren and Frolov (10). 
Subsequently, we administered mebendazole in combi-
nation with other drugs, as suggested by Bregani et al. 
(11). Since 2009, we have administered mebendazole plus 
doxycycline, according to the only available randomized 
clinical trial (4).
Our study had other limitations, which were caused 
mostly by the retrospective design. First, posttreatment fol-
low-up was available for only a few patients because most 
resided only temporarily in Italy. Thus, we could not prop-
erly describe response to treatment. Second, most patients 
came to our center because of symptoms or an increased 
eosinophil count. Thus, the proportion of symptomatic pa-
tients is not representative of the general population with 
M. perstans nematode infections.
In summary, infection with M. perstans nematodes 
should be included in the differential diagnosis of patients 
with eosinophilia who have lived in disease-endemic 
countries. Serologic analysis (ELISA for filariae) can be 
used for screening, and detection of microfilaremia in pe-
ripheral blood should be performed for patients with posi-
tive serologic results.
Dr. Gobbi is a specialist in infectious diseases at the Center for 
Tropical Diseases, Sacro Cuore Hospital, Verona, Italy. His 
primary research interests are malaria, arbovirosis surveillance, 
and neglected tropical diseases.
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